Table 2 The expression profile of LILRB1 mRNA and clinicopathological glioma risk variables in TCGA.
Characteristic | Low expression of LILRB1 | High expression of LILRB1 | p |
|---|---|---|---|
n | 348 | 348 | Â |
WHO grade, n (%) |  |  | < 0.001 |
G2 | 149 (23.5%) | 75 (11.8%) | Â |
G3 | 119 (18.7%) | 124 (19.5%) | Â |
G4 | 41 (6.5%) | 127 (20%) | Â |
IDH status, n (%) |  |  | < 0.001 |
WT | 69 (10.1%) | 177 (25.8%) | Â |
Mut | 275 (40.1%) | 165 (24.1%) | Â |
1p/19q codeletion, n (%) |  |  | < 0.001 |
codel | 151 (21.9%) | 20 (2.9%) | Â |
non-codel | 195 (28.3%) | 323 (46.9%) | Â |
Gender, n (%) | Â | Â | 0.055 |
Female | 162 (23.3%) | 136 (19.5%) | Â |
Male | 186 (26.7%) | 212 (30.5%) | Â |
Race, n (%) | Â | Â | 0.959 |
Asian | 6 (0.9%) | 7 (1%) | Â |
Black or African American | 16 (2.3%) | 17 (2.5%) | Â |
White | 317 (46.4%) | 320 (46.9%) | Â |
Age, n (%) | Â | Â | 0.005 |
<=60 | 292 (42%) | 261 (37.5%) | Â |
> 60 | 56 (8%) | 87 (12.5%) |  |